Surmodics (STU:SU6) LT-Debt-to-Total-Asset : 0.18 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Surmodics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Surmodics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.18.

Surmodics's long-term debt to total assets ratio declined from Mar. 2023 (0.20) to Mar. 2024 (0.18). It may suggest that Surmodics is progressively becoming less dependent on debt to grow their business.

Surmodics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Surmodics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics LT-Debt-to-Total-Asset Chart

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.17

Surmodics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.20	0.17	0.17	0.18	0.18

Surmodics LT-Debt-to-Total-Asset Calculation

Surmodics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )	/	Total Assets (A: Sep. 2023 )
	=	30.339	/	174.032
	=	0.17

Surmodics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	30.047	/	168.181
	=	0.18

Surmodics (STU:SU6) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Surmodics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Surmodics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics (STU:SU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (STU:SU6) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SRDX:USA SU6:Germany

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Surmodics (STU:SU6) Headlines

No Headlines